Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2008 1
2009 1
2010 3
2011 3
2014 1
2015 1
2016 3
2017 3
2018 3
2019 1
2020 4
2021 4
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
The future of precise cancer chronotherapeutics.
Innominato PF, Karaboué A, Bouchahda M, Bjarnason GA, Lévi FA. Innominato PF, et al. Among authors: bouchahda m. Lancet Oncol. 2022 Jun;23(6):e242. doi: 10.1016/S1470-2045(22)00188-7. Lancet Oncol. 2022. PMID: 35654059 No abstract available.
Reply to P. Gazzaniga et al.
Bouchahda M, Saffroy R, Karaboué A, Hamelin J, Innominato P, Saliba F, Bosselut N, Lemoine A, Lévi F. Bouchahda M, et al. JCO Precis Oncol. 2021 Nov;5:391-392. doi: 10.1200/PO.20.00465. JCO Precis Oncol. 2021. PMID: 34994602 No abstract available.
Multicentre, interventional, single-arm study protocol of telemonitored circadian rhythms and patient-reported outcomes for improving mFOLFIRINOX safety in patients with pancreatic cancer (MultiDom, NCT04263948).
Bouchahda M, Ulusakarya A, Thirot-Bidault A, Attari A, Bossevot R, Tuligenga R, Hammel P, Adam R, Levi F. Bouchahda M, et al. BMJ Open. 2023 Jun 7;13(6):e069973. doi: 10.1136/bmjopen-2022-069973. BMJ Open. 2023. PMID: 37286324 Free PMC article.
Circadian rest-activity rhythm as an objective biomarker of patient-reported outcomes in patients with advanced cancer.
Innominato PF, Komarzynski S, Palesh OG, Dallmann R, Bjarnason GA, Giacchetti S, Ulusakarya A, Bouchahda M, Haydar M, Ballesta A, Karaboué A, Wreglesworth NI, Spiegel D, Lévi FA. Innominato PF, et al. Among authors: bouchahda m. Cancer Med. 2018 Sep;7(9):4396-4405. doi: 10.1002/cam4.1711. Epub 2018 Aug 7. Cancer Med. 2018. PMID: 30088335 Free PMC article.
Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5-fluorouracil and leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial.
Innominato PF, Karaboué A, Focan C, Chollet P, Giacchetti S, Bouchahda M, Ulusakarya A, Torsello A, Adam R, Lévi FA, Garufi C. Innominato PF, et al. Among authors: bouchahda m. Int J Cancer. 2021 May 15;148(10):2512-2521. doi: 10.1002/ijc.33422. Epub 2020 Dec 10. Int J Cancer. 2021. PMID: 33270911 Free PMC article.
30 results